As Americans looking for greatness, we mustn’t turn a blind eye to profitability of marijuana and hemp, and what modern science will be able to achieve through the incredibly popular plant.
Today, more than half of our United States have either legalized or decriminalized marijuana in one form or another, whether it be the strict medicinal uses in a handful of locales, or the outright recreational availability of ganga in places such as Colorado or Washington State.
Heck, even in the deep south, major cities are allowing small portions of pot to be considered citation misdemeanors for possession with no jail time attached. This is simply good legislating by our government, who shouldn’t have had any say on the matter in the first place. (But that’s an entirely different saga).
Now, as the tide is turning, and the President has already indicated his willingness to end America’s federal prohibition of the plant, the FDA has made an enormous step toward common sense on the subject.
The Food and Drug Administration on Monday approved the country’s first drug derived from marijuana, a medication that treats two rare and devastating forms of epilepsy.
The drug, GW Pharmaceuticals’ Epidiolex, is made of cannabidiol, or CBD, a component of marijuana that does not give users a high. It is given as an oil, and in clinical trials, it was shown to reduce the number of seizures by about 40 percent in patients with Dravet or Lennox-Gastaut syndromes.
“This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies,” FDA Commissioner Scott Gottlieb said in a statement. “And, the FDA is committed to this kind of careful scientific research and drug development.”
Trending: Science is Settled
There are still a few hurdles to overcome, but they are part of a very worthy workload.
Before GW can market Epidiolex, though, the Drug Enforcement Administration will have to reclassify CBD, which in this case, because it comes from marijuana, is considered a Schedule I drug, meaning it has no medical value and a high risk of abuse. The agency is expected to do so within 90 days.
“This approval is the culmination of GW’s many years of partnership with patients, their families, and physicians in the epilepsy community to develop a much needed, novel medicine,” GW CEO Justin Gover said in a statement. “These patients deserve and will soon have access to a cannabinoid medicine that has been thoroughly studied in clinical trials, manufactured to assure quality and consistency, and available by prescription under a physician’s care.”
I’ve said it before, and I will say it again; there is very little downside to the continued proliferation of the pot plant, and you don’t have to smoke legal marijuana to reap the benefits of legal marijuana. The green gold rush is a very well documented phenomenon in states where it is considered legal, as well as incredibly worthwhile developments in the realm of medicine and addiction as well.